GI Bleeding in the Era of Continuous- Flow Left Ventricular Assist Devices
|
|
- Eugene Webb
- 6 years ago
- Views:
Transcription
1 GI Bleeding in the Era of Continuous- Flow Left Ventricular Assist Devices Patrick Wieruszewski, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds March 7, MFMER slide-1
2 Objectives Discuss the history of left ventricular assist devices and the associated complications postimplantation Review the pathophysiology of gastrointestinal bleeding in patients with left ventricular assist devices Identify potential pharmacologic options for the treatment and prevention of gastrointestinal bleeding 2017 MFMER slide-2
3 % Mortality Heart Failure in the United States 6.5 million affected and rising 250,000 with end-stage heart failure 1 million new cases annually Years After Diagnosis Benjamin EJ et al. Circulation 2017;ahead of print. Fosbol EL et al. Circ Heart Fail 2009;2(6): Roger VL. Circ Res 2013;113(6): MFMER slide-3
4 Left Ventricular Assist Devices (LVADs) 1966 First LVAD (wean to recovery) 1970 NIH LVAD working group formed 1978 First LVAD implanted as BTT 1984 First Successful LVAD for BTT Baylor Medicine, ca NIH = National Institutes of Health BTT = Bridge to Transplantation 1990s Interest declined due to complications DeBakey ME. Am J Cardiol 1971;27(1):3-11. Stewart GC et al. Circulation 2012;125(10): MFMER slide-4
5 Survival (probability) REMATCH (2001) LVAD Medical therapy p = Months Rose EA et al. N Eng J Med 2001;345(20): MFMER slide-5
6 Survival (probability) Continuous-Flow HeartMate II Continuous LVAD (2009) Medical therapy (2001) Pulsatile LVAD (2009) Pulsatile LVAD (2001) p = (2009) p = 0.09 (2001) Months Rose EA et al. N Eng J Med 2001;345(20): Salughter MS et al. N Eng J Med 2009;361(23): Fang JC. N Eng J Med 2009;361(23): MFMER slide-6
7 # Patients Trends in Heart Transplantation 6000 Wait List Additions #Transplanted LVAD Implants Year United Network for Organ Sharing INTERMACS Statistical Report MFMER slide-7
8 Incidence (%) Complications of Continuous-Flow LVADs Starling RC et al. J Am Coll Cardiol 2011;57(19): MFMER slide-8
9 Incidence (%) Complications of Continuous-Flow LVADs Infection Bleeding Arrhythmias Respiratory Failure Starling RC et al. J Am Coll Cardiol 2011;57(19): MFMER slide-9
10 Pump Thrombosis at 1 year (%) Iatrogenic Anticoagulation HeartMate II 6 4 2? Year of Implantation Stulak JM et al. N Eng J Med 2014;370(15): Meyer AL et al. J Thorac Cardiovasc Surg 2008;135(1): MFMER slide-10
11 Clotters vs. Bleeders Characteristic* PT (n = 8) No PT (n = 56) p-value GIB (n = 15) No GIB (n = 49) p-value Age, mean Female 4 (50) 9 (16) (33) 8 (16) 0.15 Prior VTE 1 (13) 7 (13) (7) 7 (14) 0.44 Prior GIB 0 (0) 3 (5) (0) 3 (6) 0.33 INR, mean Antiplatelet 1 (13) 28 (50) (47) 23 (47) 0.99 *n (%) unless otherwise noted PT = Pump thrombosis GIB = GI Bleed Lopilato AC et al. Artif Organs 2015;39(11): MFMER slide-11
12 % patients More at Play? LVAD (n = 159) Control (n = 159) p-value Age (y) 55±13 64±15 <0.001 Male 121 (76%) 90 (57%) <0.001 INR at GIB 2.3± ±2.2 NS p <0.001 p = p = GIB GIAD Thrombotic event 17 8 LVAD Control GIB = GI Bleed GIAD = GI angiodysplasia Shrode CW et al. Clin Gastroenterol Hepatol 2014;12(9): MFMER slide-12
13 Acquired von Willebrand Syndrome vwf multimer deficiency Shear stress vwf = von Willebrand Factor vwf deformation Impaired plateletmediated homeostasis Proteolysis (ADAMTS13) Nascimbene A et al. Blood 2016;127(25): Crow S et al. Ann Thorac Surg 2010;90: MFMER slide-13
14 Arteriovenous Malformations Pseudo-Heyde Syndrome Narrow pulse pressure Intraluminal pressure Mucosal vein dilation BLEEDING vwf deficiency Anticoagulation Stress Mayo Foundation for Medical Education and Research Heyde EC et al. N Eng J Med 1958;259:941. Cushing K et al. Dig Dis Sci 2016;61: MFMER slide-14
15 Proportion of patients (%) Proportion of causes (%) Hospital Readmissions 115 CF-LVADs, follow-up ~1.5 years 29% with 1 readmission 15% with 2 readmissions 29% with >2 readmissions Bleeding Cardiac Infection Thrombosis Biliary Pump related Other Elective CF-LVAD = Continuous-flow LVAD Hasin T et al. J Am Coll Cardiol 2013;61(2): MFMER slide-15
16 # procedures per event prbcs per event Morbidity and Mortality Deaths related to LVAD GIB are rare Morbidity is significant Kushiner et al. Stern et al. Marsano et al. 0 Morgan et al. Kushnir et al. Stern et al. Marsano et al. prbc = packed red blood cells GIB = GI Bleed Kushnir VM et al. Gastrointest Endosc 2012;75: Stern DR et al. J Card Surg 2010;25: Marsano J et al. Dig Dis Sci 2015;60: Morgan JA et al. J Heart Lung Transplant 2012;31: MFMER slide-16
17 % patients Diagnostic Evaluation Clinical suspicion Bleeding source identified in only ~50% Etiology AVM Ulcer Polyp Erosion Hemorrhoid Diverticula Cushing K et al. Dig Dis Sci 2016;61: MFMER slide-17
18 Treatment Approach Resuscitation Transfusions Reversal typically avoided Local intervention during scoping Pump speed reduction Empiric proton pump inhibitors Adjustment of anticoagulation program Pharmacologic therapy for recurrence 2017 MFMER slide-18
19 Anticoagulation Program Patient specific No standardized, validated approach developed Anticoagulant INR INR INR d/c warfarin Antiplatelet Aspirin 325mg Aspirin 81mg d/c aspirin 2017 MFMER slide-19
20 Danazol Synthetic androgen Progestin-like effects Inhibits IL-1 and TNF-α Vascular stability Treatment considerations Thromboembolic events Hepatotoxic Intracranial hypertension Teratogenic Mori H et al. Am J Reprod Immunol 1990;24(2): MFMER slide-20
21 Danazol in LVADs 59 y/o male s/p HMII 9 hospitalizations for GIB 40 prbcs 7 EGDs 8 other scopes (AVMs) Danazol 200mg twice daily x 49 days No GIB x 9 months Schettle et al. (n = 19) Before Danazol After Danazol Mean prbcs (n) Mean hospitalizations (n) Falls et al. (n = 5) Mean time between hospitalizations (m) HM = HeartMate II GIB = GI Bleed prbc = packed red cells EGD = esophagogastroduodenoscopy AVM = ateriovenous malformation Schettle et al. J Heart Lung Transplant 2014;33(5): Schettle et al. J Heart Lung Transplant 2016;35(4S):S83. Falls et al. J Heart Lung Transplant 2016;35(4S):S MFMER slide-21
22 Plasma levels of VEGF (pg/ml) Thalidomide Mechanism Anti-angiogenic Inhibits VEGF p < Treatment considerations Prothrombotic Bone marrow suppression Fluid retention Neuropathy Teratogenic Thalomid REMS Special handling 0 Pre-thalidomide Post-thalidomide VEGF = vascular endothelial growth factor REMS = Risk evaluation and mitigation strategies Bauditz J et al. World J Gastroenterol 2007;13(45): Ge ZZ et al. Gastroenterology 2011;141(5): MFMER slide-22
23 Thalidomide in LVADs Patient Age # episodes Documented AVM GIB Effect Other outcome Yes No recurrence Yes No recurrence Yes No recurrence Discontinued (AE) Yes No recurrence Discontinued (AE) No No recurrence Dose reduction (AE) No Reduced bleeding Transplanted Yes No recurrence Transplanted Yes Reduced bleeding Expired Yes - Expired No No recurrence Discontinued (AE)* No No recurrence Discontinued (AE) No No recurrence No No recurrence - *recurrent GIB after discontinuation AVM = arteriovenous malformation AE = adverse event Ray R et al. ASAIO J 2014;60: Ray R et al. J Heart Lung Transplant 2015;34(1): Chan LL et al. Heart Lung Circ 2017; ahead of print MFMER slide-23
24 Octreotide Somatostatin analog splanchnic blood flow Inhibits angiogenesis Improves platelet aggregation Treatment considerations Relatively benign GI disturbances Increased blood pressure Impairment of glucose homeostasis Malhorta R et al. ASAIO J 2017;ahead of print MFMER slide-24
25 Octreotide in LVADs Hayes et al. (2010) Retrospective analysis of CF-LVADs (n = 5 received octreotide) Averaged 2 prior GIB events Received 25mcg/min infusion, 100mcg SQ BID or 10mg IM q4weeks GI bleeding was successfully treated Aggarwal et al. (2012) Retrospective analysis of CF-LVADs (n = 13 received octreotide) Dosing not reported (SQ or continuous infusions used) No differences noted in mortality, rebleeding, length of stay, or usage of prbcs, FFP, Cryo, platelets Hayes HM et al. Artif Organs 2010;34(9): Aggarwal A et al. Ann Thorac Surg 2012;93(5): MFMER slide-25
26 Octreotide in LVADs Loyaga- Rendon et al. (2015) Case series (n = 7) Averaged 3 prior GIB admissions (14 prbcs) Received 50mcg SQ BID or LAR 20mg IM q4weeks Non-significant reduction in hospitalization, prbcs, and diagnostic procedures Safety: abdominal cramps, diarrhea Malhorta et al. (2017) Prospective analysis (n = 10) Only 3 patients with prior GIB Received LAR 20mg IM q4weeks x 28 weeks No recurrent GIB at 28 weeks Possible VEGF benefits Safety: no adverse effects reported Loyaga-Rendon RY et al. ASAIO J 2015;61(1): Malhorta R et al. ASAIO J 2017;ahead of print MFMER slide-26
27 Other Potential Options Doxycycline von Willebrand factor concentrate Hormones Anti-fibrinolytics Desmopressin Angiotensin II antagonizers 2017 MFMER slide-27
28 Clinical Vignette 64 y/o male with history notable for end-stage ischemic cardiomyopathy s/p HeartMate II implantation as DT 60 days prior now presents with melanotic stools, coffee ground emesis, and syncopal event this morning EMS Hemodynamically stable, Hgb 8, INR 1.8 Transfused 2 prbcs 2017 MFMER slide-28
29 Clinical Vignette Admission history since LVAD implant 1 st admission EGD with APC for angioectasias 2 nd admission EGD with APC and clipping for AVM in the gastric antrum INR goal adjusted to Current anticoagulation program Warfarin, adjusted to INR goal Aspirin 325mg daily 2017 MFMER slide-29
30 Question 1 What factors are probably contributing to gastrointestinal bleeding in this patient? A. Older age B. Anticoagulation C. LVAD D. Previous GI bleeding E. All of the above 2017 MFMER slide-30
31 Diagnostic Evaluation Repeat blood draw reveals Hgb 9.9, INR 2.0 Hemodynamically stable Interrogation of LVAD reveals normal functioning, with no power spikes GI bleed team consulted and patient taken to EGD suite 2017 MFMER slide-31
32 Question 2 What is the likely etiology of gastrointestinal bleeding in this patient? A. Peptic ulcer B. Hemorrhoid C. Arteriovenous malformation D. Rectal ulcer 2017 MFMER slide-32
33 Diagnostic Evaluation Findings on EGD Altered blood/coffee ground-like material in the gastric antrum, gastric fundus, and gastric body One bleeding angioectasia found in the stomach Treated with APC and clips placed 2017 MFMER slide-33
34 Question 3 Based on the presentation, how would you approach the future prevention of GI bleeding in this patient? A. Discontinue warfarin B. Danazol 200 mg BID C. Octreotide LAR 20mg IM q4weeks D. Change warfarin to apixaban 2017 MFMER slide-34
35 Conclusions LVADs provide survival benefit but increase the risk of GI bleeding GI bleeding in LVADs is multifactorial and complex While limited prospective data exist, there are emerging therapies that have prevented GI bleeding in patients with LVADs 2017 MFMER slide-35
36 If you can think of how much love there would be in hundreds of hearts, then that is how much love there is in a plastic heart Michael E DeBakey, MD ca MFMER slide-36
37 Questions & Discussion 2017 MFMER slide-37
38 GI Bleeding in the Era of Continuous- Flow Left Ventricular Assist Devices Patrick Wieruszewski, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds March 7, MFMER slide-38
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel No disclosures Probability of survival Survival (%) Survival with LVAD Destination Bridge
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More informationMultiple case reports of successful use, with only one case report of intra device thrombotic event
rfviia in VAD Patients Limited data exist regarding safety Multiple factors increase pro thrombotic potential Multiple case reports of successful use, with only one case report of intra device thrombotic
More informationHHS Public Access Author manuscript J Card Fail. Author manuscript; available in PMC 2018 April 12.
Long-acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients with a Continuous-Flow Left Ventricular Assist Device Colleen Juricek, RN a,*, Teruhiko Imamura, MD, PhD b,*, Ann
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More information2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants Wednesday, May 9, 2018, 12:00PM ET Guest Author: Adam Cuker, MD Presenter: Tracy Minichiello, MD
More informationIncidence and Management of Gastrointestinal Bleeding With Continuous Flow Assist Devices
Incidence and Management of Gastrointestinal Bleeding With Continuous Flow Assist Devices Ashim Aggarwal, MD, MRCP, Rojina Pant, MD, Shivani Kumar, Priya Sharma, BA, Colleen Gallagher, BSN, Antone J. Tatooles,
More informationEndoscopic Management of Vascular Lesions of the GI tract
Endoscopic Management of Vascular Lesions of the GI tract Lake Louise, June 2014 Sergio Zepeda Gómez MD Assistant Professor Division of Gastroenterology University of Alberta, Edmonton Best Practice &
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationReadmissions: an unavoidable nemesis
Readmissions: an unavoidable nemesis This presentation was presented at the Thoratec Corporation Economic Summit held on September 30-October 2 in La Jolla, CA. Please note that this presentation and content
More informationPeri-Endoscopic Period. Neena S. Abraham MD, MSCE, FACG
How to Manage Antiplatelet Therapy in the Peri-Endoscopic Period Neena S. Abraham MD, MSCE, FACG Michael E. DeBakey Veterans Affairs Medical Center Sections of Gastroenterology & Health Services Research
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationPerioperative Management of the Mechanical Circulatory Support Patient. American Association of Thoracic Surgeons Allied Health Symposium May 4, 2013
Perioperative Management of the Mechanical Circulatory Support Patient American Association of Thoracic Surgeons Allied Health Symposium May 4, 2013 Disclosures None 2012 MFMER slide-2 Objectives Review
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationDiagnosis of Device Thrombosis
Diagnosis of Device Thrombosis Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's Medical Center / Texas Heart Institute Trends in
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationThe Cardiogastroenterologist: Managing Antiplatelet and Antithrombotic Drugs. Do the following clinical scenarios make you tachycardic?
The Cardiogastroenterologist: Managing Antiplatelet and Antithrombotic Drugs Neena S. Abraham MD, MSc (EPID), FACG Professor of Medicine, Mayo Clinic College of Medicine Arizona Site Director, Mayo Clinic
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationHeart Transplantation
Heart Transplantation Age and Outcome Mayo Clinic Richard Daly, MD Professor of Surgery Surgical Director Heart & Lung Transplantation 2014 MFMER 3346076-1 Rochester, Minnesota 2014 MFMER 3346076-2 The
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationAnalysis of Pump Thrombosis in the Intermacs Database
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationLower GI bleeding Management DR EHSANI PROFESSOR IN GASTROENTEROLOGY AND HEPATOLOGY
Lower GI bleeding Management DR EHSANI PROFESSOR IN GASTROENTEROLOGY AND HEPATOLOGY 15 FEB 2018 Sources Sources Sources Initial evaluation History Physical examination Laboratory evaluation Obtained at
More informationManagement of Lower Gastrointestinal Bleeding. Patrick Lau Department of Surgery Kwong Wah Hospital
Management of Lower Gastrointestinal Bleeding Patrick Lau Department of Surgery Kwong Wah Hospital Lower Gastrointestinal bleeding The challenge Account for 20% of gastrointestinal bleeding 80% stopped
More information5/15/2018. Reduced Platelet Activity
ASSOCIATION OF DESMOPRESSIN ACETATE ON OUTCOMES IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS ON ANTIPLATELET THERAPY Jessica McManus, Pharm. D. PGY2 Critical Care Pharmacy Resident UF Health Jacksonville
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationEMS and Nursing Considerations in VAD Patient Care
EMS and Nursing Considerations in VAD Patient Care B R I T T A N Y B U T Z L E R B S N R N V A D C O O R D I N A T O R F R O E D T E R T A N D T H E M E D I C A L C O L L E G E O F W I 1 0 / 2 5 / 1 8
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationThe Balancing Act Bleeding and Thrombosis in MCS. Muhammad Adil Soofi
The Balancing Act Bleeding and Thrombosis in MCS Muhammad Adil Soofi Road Map Survival and complications with LVAD What is the Burden of thrombosis and bleeding Why Bleeding and Thrombosis happen When
More informationDefinitive Surgical Treatment When Endoscopy Fails. Erik Peltz D.O. Resident Debate February 26 th 2007 University of Colorado Dept.
Nonvariceal Gastrointestinal Hemorrhage: Definitive Surgical Treatment When Endoscopy Fails Erik Peltz D.O. Resident Debate February 26 th 2007 University of Colorado Dept. Surgery Non-Variceal Upper GI
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationon Anti-coagulants -- Is It Safe? And When to Stop?
Endoscopy for Your Patient on Anti-coagulants -- Is It Safe? And When to Stop? John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationComplications of Contemporary Continuous Flow LVAD Therapy
Complications of Contemporary Continuous Flow LVAD Therapy Daniel J. Goldstein MD FACS FACC Associate Professor Vice-Chair, Dept Cardiothoracic Surgery Disclosures Thoratec Inc Medical Advisory Board Chair,
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationOn-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding
On-Call Upper GI Bleeding John R Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Upper Gastrointestinal Bleeding 300,000000 hospitalizations/year
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationUGI BLEED. Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore
UGI BLEED Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore Outline UGI bleed: etiology and presentation Management: Non variceal / variceal bleed
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationYes No Unknown. Major Infection Information
Rehospitalization Intervention Check any that occurred during this hospitalization. Pacemaker without ICD ICD Atrial arrhythmia ablation Ventricular arrhythmia ablation Cardioversion CABG (coronary artery
More informationJournal of the American College of Cardiology Vol. 53, No. 23, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 53, No. 23, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.02.048
More informationAortic Insufficiency: How Often Does It Occur and When To Treat
Aortic Insufficiency: How Often Does It Occur and When To Treat Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester,
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationAntiplatelets in cardiac patients with suspected GI bleeding
Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding
More informationThe following content was supplied by the author as supporting material and has not been copy-edited or verified by JBJS.
Page 1 The following content was supplied by the author as supporting material and has not been copy-edited or verified by JBJS. Appendix TABLE E-1 Care-Module Trigger Events That May Indicate an Adverse
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationJournal of the American College of Cardiology Vol. 56, No. 15, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 56, No. 15, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.05.016
More informationDuring the past several decades, left ventricular assist
Advances in Heart Failure Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices Jorge Suarez, BS; Chetan B. Patel, MD; G. Michael Felker, MD; Richard Becker, MD;
More informationLVADs as Destination Therapy: When Best Practice Criteria Meets the Real World
LVADs as Destination Therapy: When Best Practice Criteria Meets the Real World Farooq Sheikh, M.D., FACC Advanced Heart Failure Program MedStar Washington Hospital Center Disclosure I have no relevant
More informationBleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy?
Editorial Bleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy? Snehal R. Patel, Sasa Vukelic, Ulrich P. Jorde Division of Cardiology, Montefiore Medical Center,
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationKnowing your treatment options can give you hope for a longer, better life
Heart failure is a deadly disease Knowing your treatment options can give you hope for a longer, better life With heart failure, it was not a matter of if I would get worse; it was a matter of when, and
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationAcquired Von Willebrand Syndrome and Heyde s Syndrome. Debra L. Smith, MD, PhD Hematology Fellows Conference April 8, 2016
Acquired Von Willebrand Syndrome and Heyde s Syndrome Debra L. Smith, MD, PhD Hematology Fellows Conference April 8, 2016 Objectives Describe acquired von Willebrand syndrome (AVWS) clinical presentation
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationMedical Therapy after LVAD
Medical Therapy after LVAD Maria Frigerio 2nd Section of Cardiology, Heart Failure & Cardiac Transplant Unit DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy Heart failure therapy in LVAD pts A
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Oakland K, Jairath V, Uberoi R, et al. Derivation
More informationEchocardiographic Structural Assessment Pre- LVAD
None Disclosures Echocardiographic Structural Assessment Pre- LVAD LVEF ( 25% for DT LVAD) Right ventricle Valvular disease Intra- cardiac shunts Intra- cardiac thrombi Ascending aorta Case 1 50 yo M
More informationFurther devices to treat heart failure
Postgraduate Course Heart Failure Further devices to treat heart failure Pr. Matthias Kirsch Department of Cardiac Surgery Centre Hospitalo-Universitaire Vaudois Université de Lausanne e-mail: matthias.kirsch@chuv.ch
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationFirst Experiences With the HeartWare Ventricular Assist System in Children
First Experiences With the HeartWare Ventricular Assist System in Children Oliver Miera, MD, Evgenij V. Potapov, MD, PhD, Matthias Redlin, MD, Alexander Stepanenko, MD, Felix Berger, MD, PhD, Roland Hetzer,
More informationOral anti-thrombotic therapy-management in patients requiring endoscopy
Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients
More informationWhen to Scope in Lower GI Bleeding: It Must Be Done Now. Lisa L. Strate, MD, MPH Assistant Professor of Medicine University of Washington, Seattle, WA
When to Scope in Lower GI Bleeding: It Must Be Done Now Lisa L. Strate, MD, MPH Assistant Professor of Medicine University of Washington, Seattle, WA Outline Epidemiology Overview of available tests Urgent
More informationGASTROINESTINAL BLEEDING. Dr.Ammar I. Abdul-Latif
GASTROINESTINAL BLEEDING Dr.Ammar I. Abdul-Latif CLASSIFICATION OF G.I.BLEEDING GIB Appearance Acuity Site Apparent Acute Upper Obscure Chronic Lower UPPER&LOWER G.I.BLEEDING CAUSES OF UPPER G.I. BLEEDING
More informationAnticoagulants are a contributing factor. Other causes are Mallory-Weiss tears, AV malformations, and malignancy and aorto-enteric fistula.
Upper GI Bleeding EMU2018 Dr. Walter Himmel MD Incidence: In non-cirrhotics, the commonest causes are peptic ulcer disease (50%) followed by erosive gastritis. In cirrhotic patients, variceal bleeding
More informationReadmissions After Ventricular Assist Device: Etiologies, Patterns, and Days Out of Hospital
Readmissions After Ventricular Assist Device: Etiologies, Patterns, and Days Out of Hospital Stephen J. Forest, MD, Ricardo Bello, MD, PhD, Patricia Friedmann, MS, Danielle Casazza, RN, Cecilia Nucci,
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationUpper gastrointestinal bleeding in children. Nguyễn Diệu Vinh, MD Department of Gastroenterology
Upper gastrointestinal bleeding in children Nguyễn Diệu Vinh, MD Department of Gastroenterology INTRODUCTION Upper gastrointestinal (UGI) bleeding : arising proximal to the ligament of Treitz in the distal
More informationHFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy
HFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy ESC- HFA criteria for Adv-HF Severe symptoms of HF (NYHA class III or IV) with episodes of fluid retention and/or peripheral
More informationOriginal Article. Gastrointestinal bleeding in acute pancreatitis: etiology, clinical features, risk factors and outcome
Tropical Gastroenterology 2015;36(1):31 35 Original Article Gastrointestinal bleeding in acute pancreatitis: etiology, clinical features, risk factors and outcome Surinder S Rana 1, Vishal Sharma 1, Deepak
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationUpper Gastrointestinal Bleeding Score for Differentiating Variceal and Nonvariceal Upper Gastrointestinal Bleeding ABSTRACT
44 Original Article Upper Gastrointestinal Bleeding Score for Differentiating Variceal and Jaroon Chasawat Varayu Prachayakul Supot Pongprasobchai ABSTRACT Background: Upper gastrointestinal bleeding (UGIB)
More informationRole of radiology in colo-rectal bleedings. Alban DENYS MD FCIRSE EBIR CHUV LAUSANNE
Role of radiology in colo-rectal bleedings Alban DENYS MD FCIRSE EBIR CHUV LAUSANNE Epidemiology Lower GI bleeding accounts for 20-25% of all GI bleeding Annual incidence in USA :21-27/100000 Longstreth
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationKathy P. Bull-Henry, MD, FACG Dr. Bull-Henry has indicated no relevant financial relationships. Don t Waste Time With No Chance to See
Don t Waste Time with No Chance to See Kathy P. Bull-Henry, MD, FACG Dr. Bull-Henry has indicated no relevant financial relationships. Don t Waste Time With No Chance to See Kathy Bull-Henry, MD, FACG
More informationVentricular Assist Devices for Chronic Heart Failure
Ventricular Assist Devices for Chronic Heart Failure Σ.Γ.Δράκος, Επικ. Καθ/τής Medical Director, Cardiac Mechanical Support Program Investigator, Molecular Medicine Program University of Utah Heart Failure:
More information